8 results for: atopic dermatitis

Ebglyss

Drug name: Ebglyss | Dosage form: Injection (subcutaneous; 250 mg/2 mL in a single-dose prefilled pen, 250 mg/2 mL in a single-dose prefilled syringe with needle shield) | Approval year: 2024 | Company: Eli Lilly and Company | Class: interleukin-13 antagonists | System: Skin

Indications

Indicated for the treatment of adult and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.

Document title: Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255974/?report=printable Document source: JAMA Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: EBGLYSS (lebrikizumab-lbkz) Prescribing Information. Document link: https://pi.lilly.com/us/ebglyss-uspi.pdf?s=pi&redirect-referrer=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Ffda-approves-lillys-ebglysstm-lebrikizumab-lbkz-adults-and Document source: Eli Lilly and Company, Indianapolis, IN Document type: Product Monograph / Prescribing Information Document year: 2024

Document title: Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Document link: https://www.annallergy.org/action/showPdf?pii=S1081-1206%2823%2901455-2 Document source: Annals of Allergy, Asthma & Immunology Document type: Clinical Practice Guidelines Document year: 2024

Document title: Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). Document link: https://www.minervamedica.it/en/getfreepdf/U2VZVS91UElMSFJuN1pZR0ozczNrS1hqWVhodUdLN1hjRG1vNkN1R2ZOeDdFWFhmVG1HbnFvVWozditvNEJiNQ%253D%253D/R23Y2024N03A0223.pdf Document source: Italian Journal of Dermatology and Venereology Document type: Clinical Practice Guidelines Document year: 2024

Document title: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over. NICE Technology appraisal guidance number TA986. Document link: https://www.nice.org.uk/guidance/ta986/resources/lebrikizumab-for-treating-moderate-to-severe-atopic-dermatitis-in-people-12-years-and-over-pdf-82615913759941 Document source: National Institute for Health and Care Excellence Document type: Clinical Practice Guidelines Document year: 2024

Document title: Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. Document link: https://www.jacionline.org/action/showPdf?pii=S0091-6749%2823%2901112-0 Document source: The Journal of Allergy and Clinical Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Incidence of conjunctivitis adverse event in patients treated with biologics for atopic dermatitis: A systematic review and meta-analysis. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472279/pdf/main.pdf Document source: JAAD International Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884690/pdf/fmed-09-1091271.pdf Document source: Frontiers in Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.18345 Document source: Journal of the European Academy of Dermatology and Venereology Document type: Clinical Practice Guidelines Document year: 2022

Document title: The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364267/pdf/fimmu-13-923362.pdf Document source: Frontiers in Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Biological Therapies for Atopic Dermatitis: A Systematic Review. Document link: https://karger.com/drm/article/237/4/542/114746/Biological-Therapies-for-Atopic-Dermatitis-A Document source: Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis. Document link: https://www.tandfonline.com/doi/full/10.1080/17512433.2021.1970529 Document source: Expert Review of Clinical Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453983/pdf/JDV-35-1797.pdf Document source: Journal of the European Academy of Dermatology and Venereology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Cibinqo

Indications

Indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Document title: Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate‑to‑severe atopic dermatitis in randomized, double‑blind and placebo‑controlled trials: A systematic review and a meta‑analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11019643/pdf/br-20-05-01772.pdf Document source: Biomedical Reports Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The changes of platelets counts in atopic dermatitis patients after treatment of abrocitinib: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110218/pdf/PDIA-41-53922.pdf Document source: Postepy Dermatologii i Alergologii Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11133567/pdf/fimmu-15-1367099.pdf Document source: Frontiers in Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962383/pdf/PDIA-41-52486.pdf Document source: Postepy Dermatologii i Alergologii Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255974/?report=printable Document source: JAMA Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253311/pdf/PDIA-41-54403.pdf Document source: Postȩpy Dermatologii i Alergologii Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10921355/pdf/fimmu-15-1342810.pdf Document source: Frontiers in Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11017148/ Document source: Health Technology Assessment Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: A systematic review in pediatric patients Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/pde.15468 Document source: Pediatric Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis Document link: https://academic.oup.com/bjd/article-pdf/190/2/184/56345043/ljad393.pdf Document source: British Journal of Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials Document link: https://pubmed.ncbi.nlm.nih.gov/37597261/ Document source: Journal of the European Academy of Dermatology and Venereology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Document link: https://www.jaad.org/action/showPdf?pii=S0190-9622%2823%2902878-5 Document source: Journal of the American Academy of Dermatology Document type: Clinical Practice Guidelines Document year: 2023

Document title: Cibinqo (abrocitinib) Prescribing Information. Document link: https://labeling.pfizer.com/ShowLabeling.aspx?id=16652 Document source: Pfizer Labs, New York, NY Document type: Product Monograph / Prescribing Information Document year: 2023

Document title: Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials Document link: https://www.jacionline.org/action/showPdf?pii=S0091-6749%2823%2901112-0 Document source: The Journal of Allergy and Clinical Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892442/pdf/SKI2-3-e133.pdf Document source: Skin Health and Disease Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272339/pdf/main.pdf Document source: Heliyon Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis Document link: https://link.springer.com/article/10.1007/s00011-023-01789-x Document source: Inflammation Research Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393843/ Document source: Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541568/pdf/DTH-35-e15636.pdf Document source: Dermatologic Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110624/pdf/13555_2022_Article_721.pdf Document source: Dermatology and Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928094/ Document source: JAMA Dermatol Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574696/pdf/ActaDV-102-2075.pdf Document source: Acta Dermato-venereologica Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials Document link: https://www.tandfonline.com/doi/full/10.1080/09546634.2021.1961997 Document source: The Journal of Dermatological Treatment Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470048/pdf/life-11-00927.pdf Document source: Life Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440866/pdf/fmed-08-682547.pdf Document source: Frontiers in Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis Document link: https://www.tandfonline.com/doi/full/10.1080/17512433.2021.1970529 Document source: Expert Review of Clinical Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245258/pdf/DRP2021-8382761.pdf Document source: Dermatology Research Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453983/pdf/JDV-35-1797.pdf Document source: Journal of the European Academy of Dermatology and Venereology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Biological Therapies for Atopic Dermatitis: A Systematic Review Document link: https://karger.com/drm/article/237/4/542/114746/Biological-Therapies-for-Atopic-Dermatitis-A Document source: Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Adbry

Indications

Indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
ADBRY can be used with or without topical corticosteroids.

Document title: Adbry (tralokinumab-ldrm) Prescribing Information. Document link: https://mc-df05ef79-e68e-4c65-8ea2-953494-cdn-endpoint.azureedge.net/-/media/corporatecommunications/us/therapeutic-expertise/our-product/adbrypi.pdf?rev=d8ced7cbd6874a6997427ab88a2093e0 Document source: LEO Pharma Inc., Madison, NJ Document type: Product Monograph / Prescribing Information Document year: 2024

Document title: Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA). Document link: https://www.minervamedica.it/en/getfreepdf/cUhKM3BtWFViYnBTNFlOdXpCbk1vS2pnSDBtS1ZnUm5MbG9JZzNoOW1tWW9ueEwzUHFLeHdwUkRtb0hTdjIydQ%253D%253D/R23Y2024N03A0223.pdf Document source: Italian Journal of Dermatology and Venereology Document type: Clinical Practice Guidelines Document year: 2024

Document title: Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685203/pdf/main.pdf Document source: Heliyon Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Incidence of conjunctivitis adverse event in patients treated with biologics for atopic dermatitis: A systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472279/pdf/main.pdf Document source: JAAD International Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402962/pdf/medi-102-e34516.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928094/?report=printable Document source: JAMA Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364267/pdf/fimmu-13-923362.pdf Document source: Frontiers in Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574696/pdf/ActaDV-102-2075.pdf Document source: Acta Dermato-Venereologica Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453983/pdf/JDV-35-1797.pdf Document source: Journal of the European Academy of Dermatology and Venereology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Systemic treatments for eczema: a network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128359/pdf/CD013206.pdf Document source: The Cochrane Database of Systematic Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Rinvoq

Indications

Indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
Indicated for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blocker
Indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable
Indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blocker
Indicated for the treatment of adults with moderately to severely active Crohns disease who have had an inadequate response or intolerance to one or more TNF blockers
Indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers
Indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy
Indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers

Document title: Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11017148/?report=printable Document source: Health Technology Assessment (Winchester, England) Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10868000/pdf/13075_2024_Article_3282.pdf Document source: Arthritis Research & Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis Document link: https://journals.lww.com/eurojgh/abstract/2024/05000/comparative_maintenance_performance_of_all.4.aspx Document source: European Journal of Gastroenterology & Hepatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944248/pdf/ccid-17-593.pdf Document source: Clinical, Cosmetic and Investigational Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11103324/pdf/ard-2024-225534.pdf Document source: Annals of the Rheumatic Diseases Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib Document link: https://www.tandfonline.com/doi/epdf/10.1080/13696998.2024.2333683?needAccess=true Document source: Journal of Medical Economics Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080655/pdf/fphar-15-1387585.pdf Document source: Frontiers in Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The efficacy and safety of JAK inhibitors in patients with adult-onset still's disease: A meta-analysis and systematic review Document link: https://www.sciencedirect.com/science/article/abs/pii/S156757692400972X?via%3Dihub Document source: International Immunopharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11192398/pdf/pone.0305621.pdf Document source: PloS One Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11253311/pdf/PDIA-41-54403.pdf Document source: Postepy Dermatologii i Alergologii Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11280219/pdf/pone.0306463.pdf Document source: PloS One Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Small molecules for inflammatory bowel disease and the risk of infection and malignancy: A systematic review and meta-Analysis Document link: https://www.dldjournalonline.com/article/S1590-8658(24)00882-X/abstract Document source: Digestive and Liver Disease Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and Safety of Upadacitinib for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis Document link: https://pubmed.ncbi.nlm.nih.gov/39162272/ Document source: Current Rheumatology Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11351028/pdf/12967_2024_Article_5569.pdf Document source: Journal of Translational Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis in adolescents: A systematic review and meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419427/pdf/medi-103-e39826.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10838816/pdf/12325_2023_Article_2732.pdf Document source: Advances in Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Rinvoq (upadacitinib) Prescribing Information. Document link: https://www.rxabbvie.com/pdf/rinvoq_pi.pdf Document source: AbbVie Inc., North Chicago, IL Document type: Product Monograph / Prescribing Information Document year: 2024

Document title: Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis Document link: https://link.springer.com/article/10.1007/s00393-022-01165-w Document source: Zeitschrift Für Rheumatologie Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.19426 Document source: Journal of the European Academy of Dermatology and Venereology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis Document link: https://academic.oup.com/bjd/article-pdf/190/2/184/56345043/ljad393.pdf Document source: The British Journal of Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065447/pdf/kead598.pdf Document source: Rheumatology (Oxford, England) Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies Document link: https://www.sciencedirect.com/science/article/abs/pii/S1567576923015564?via%3Dihub Document source: International Immunopharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Comparative efficacy of systemic treatments for atopic dermatitis in adults Document link: https://www.tandfonline.com/doi/full/10.1080/1744666X.2023.2291038 Document source: Expert Review of Clinical Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment Document link: https://www.sciencedirect.com/science/article/abs/pii/S1567576923017629?via%3Dihub Document source: International Immunopharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906540/?report=printable Document source: Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: The comparative efficacy and safety of biologics and small molecules for treating patients with ulcerative colitis in Portugal: a systematic literature review and network meta-analysis Document link: https://www.europeanreview.org/wp/wp-content/uploads/6744-6759-1.pdf Document source: European Review for Medical and Pharmacological Sciences Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Impact of upadacitinib on the risk of digestive events in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361017/pdf/main.pdf Document source: Heliyon Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570180/pdf/40273_2023_Article_1293.pdf Document source: PharmacoEconomics Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359573/pdf/ard-2023-224049.pdf Document source: Annals of the Rheumatic Diseases Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129949/pdf/12325_2023_Article_2490.pdf Document source: Advances in Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968274/pdf/296_2022_Article_5270.pdf Document source: Rheumatology International Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease Document link: https://eprints.whiterose.ac.uk/195167/9/APT-1934-2022R1%20CLEAN.pdf Document source: Alimentary Pharmacology & Therapeutics Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092437/pdf/APL-26-31.pdf Document source: International Journal of Rheumatic Diseases Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070072/pdf/keac500.pdf Document source: Rheumatology (Oxford, England) Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis Document link: https://gut.bmj.com/content/72/2/264.long# Document source: Gut Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Document link: https://ard.bmj.com/content/annrheumdis/82/1/3.full.pdf?with-ds=yes Document source: Annals of the Rheumatic Diseases Document type: Clinical Practice Guidelines Document year: 2023

Document title: Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809830/pdf/PDIA-40-52085.pdf Document source: Postepy Dermatologii i Alergologii Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Upadacitinib in Crohn's Disease: A Comprehensive Systematic Review of Efficacy and Safety Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10790515/pdf/cureus-0015-00000050657.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10780022/pdf/jcm-13-00034.pdf Document source: Journal of Clinical Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442487/pdf/fphar-14-1241954.pdf Document source: Frontiers in Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn's Disease: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674451/pdf/pharmaceuticals-16-01581.pdf Document source: Pharmaceuticals (Basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis Document link: https://link.springer.com/article/10.1007/s00393-021-01119-8 Document source: Zeitschrift Für Rheumatologie Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615430/pdf/medi-102-e35689.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden Document link: https://www.tandfonline.com/doi/full/10.1080/13696998.2023.2259609 Document source: Journal of Medical Economics Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis Document link: https://link.springer.com/article/10.1007/s00011-023-01789-x Document source: Et al [Inflammation Research] Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Association Between Janus Kinase Inhibitors Therapy and Mental Health Outcome in Rheumatoid Arthritis: A Systematic Review and Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964882/pdf/40744_2021_Article_409.pdf Document source: Rheumatology and Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393843/?report=printable Document source: Dermatology (Basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis Document link: https://www.tandfonline.com/doi/full/10.1080/09546634.2021.1986204 Document source: The Journal of Dermatological Treatment Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Rheumatoid arthritis and myasthenia gravis: a case-based review of the therapeutic options Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913445/pdf/10067_2022_Article_6062.pdf Document source: Clinical Rheumatology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928094/?report=printable Document source: JAMA Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952692/pdf/jpm-12-00353.pdf Document source: Journal of Personalized Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814490/pdf/fmed-09-1079323.pdf Document source: Frontiers in Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513929/pdf/41927_2022_Article_287.pdf Document source: BMC Rheumatology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410312/pdf/life-12-01159.pdf Document source: Life (Basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403856/?report=printable Document source: JAMA Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574696/pdf/ActaDV-102-2075.pdf Document source: Acta Dermato-Venereologica Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811419/?report=printable Document source: Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Comparative Efficacy and Tolerability of Janus Kinase Inhibitor Therapies for Moderate to Severe Crohn's Disease: Alpha Network Meta-analysis Document link: https://www.jgld.ro/jgld/index.php/jgld/article/view/3804/1758 Document source: Journal of Gastrointestinal and Liver Diseases Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470048/pdf/life-11-00927.pdf Document source: Life (Basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs Document link: https://link.springer.com/article/10.1007/s00393-020-00796-1 Document source: Zeitschrift Für Rheumatologie Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naive patients with rheumatoid arthritis Document link: https://link.springer.com/article/10.1007/s00393-020-00889-x Document source: Zeitschrift Für Rheumatologie Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995584/pdf/12969_2021_Article_514.pdf Document source: Pediatric Rheumatology Online Journal Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989112/pdf/10.1177_1759720X21999564.pdf Document source: Therapeutic Advances in Musculoskeletal Disease Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788060/pdf/annrheumdis-2020-218398.pdf Document source: Annals of the Rheumatic Diseases Document type: Clinical Practice Guidelines Document year: 2021

Document title: Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080865/pdf/13317_2021_Article_153.pdf Document source: Auto- Immunity Highlights Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453983/pdf/JDV-35-1797.pdf Document source: Journal of the European Academy of Dermatology and Venereology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis Document link: https://gut.bmj.com/content/71/10/1976.long# Document source: Gut Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/dth.15098 Document source: Dermatologic Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis Document link: https://ard.bmj.com/content/annrheumdis/79/6/760.full.pdf?with-ds=yes Document source: Annals of the Rheumatic Diseases Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856126/pdf/rmdopen-2020-001374.pdf Document source: RMD Open Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Document link: https://www.mayoclinicproceedings.org/action/showPdf?pii=S0025-6196%2820%2930139-7 Document source: Mayo Clinic Proceedings Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jcpt.13142 Document source: Journal of Clinical Pharmacy and Therapeutics Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467453/pdf/12325_2020_Article_1303.pdf Document source: Advances in Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286044/pdf/annrheumdis-2019-216656.pdf Document source: Annals of the Rheumatic Diseases Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis Document link: https://www.gastrojournal.org/action/showPdf?pii=S0016-5085%2820%2930011-1 Document source: Gastroenterology Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials Document link: https://link.springer.com/article/10.1007/s00393-019-0601-3 Document source: Zeitschrift Für Rheumatologie Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Document link: https://ard.bmj.com/content/annrheumdis/79/6/685.full.pdf?with-ds=yes Document source: Annals of the Rheumatic Diseases Document type: Clinical Practice Guidelines Document year: 2020

Document title: Updated Greek Rheumatology Society Guidelines for the Management of Rheumatoid Arthritis. Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361183/pdf/MJR-31-Suppl-1-163.pdf Document source: Mediterranean Journal of Rheumatology Document type: Clinical Practice Guidelines Document year: 2020

Eucrisa

Indications

Indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Document title: Topical anti-inflammatory treatments for eczema: network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11301992/pdf/CD015064.pdf Document source: The Cochrane Database of Systematic Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations Document link: https://www.annallergy.org/action/showPdf?pii=S1081-1206%2823%2901455-2 Document source: Annals of Allergy, Asthma & Immunology Document type: Clinical Practice Guidelines Document year: 2024

Document title: Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14556 Document source: Clinical and Experimental Allergy Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Eucrisa (crisaborole) Prescribing Information. Document link: https://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=5331 Document source: Pfizer Inc., New York, NY Document type: Product Monograph / Prescribing Information Document year: 2023

Document title: Safety of topical medications in the management of paediatric atopic dermatitis: An updated systematic review Document link: https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.15751 Document source: British Journal of Clinical Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials Document link: https://www.jacionline.org/action/showPdf?pii=S0091-6749%2823%2901113-2 Document source: Journal of Allergy and Clinical Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas Document link: https://www.jle.com/en/revues/ejd/e-docs/pimecrolimus_1_cream_for_mild_to_moderate_atopic_dermatitis_a_systematic_review_and_meta_analysis_with_a_focus_on_children_and_sensitive_skin_areas_344203/article.phtml Document source: European Journal of Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278032/pdf/main.pdf Document source: Current Therapeutic Research Clinical and Experimental Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Clinical practice guidelines for the diagnosis and management of atopic dermatitis Document link: https://apjai-journal.org/wp-content/uploads/2021/09/4_AP-010221-1050-No-Supplement.pdf Document source: Asian Pacific Journal of Allergy and Immunology Document type: Clinical Practice Guidelines Document year: 2021

Document title: New treatments in atopic dermatitis Document link: https://www.annallergy.org/action/showPdf?pii=S1081-1206%2820%2930572-X Document source: Annals of Allergy, Asthma & Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: Demographics and Baseline Disease Characteristics of Early Responders to Crisaborole for Atopic Dermatitis Document link: https://jddonline.com/articles/demographics-and-baseline-disease-characteristics-of-early-responders-to-crisaborole-for-atopic-derm-S1545961620P0619X/ Document source: Journal of Drugs in Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367970/pdf/13555_2020_Article_389.pdf Document source: Dermatology and Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Document title: Pharmacological management of atopic dermatitis in the elderly Document link: https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1729738 Document source: Expert Opinion on Pharmacotherapy Document type: Systematic Reviews / Meta-Analyses Document year: 2020

Opzelura

Indications

Indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
Indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Document title: Opzelura (ruxolitinib) Prescribing Information. Document link: https://www.incytepicentral.com/sites/g/files/hssmmz4016/files/2024-08/opzelura-prescribing-information.pdf#page=1 Document source: Incyte Corporation, Wilmington, DE Document type: Product Monograph / Prescribing Information Document year: 2024

Document title: Efficacy and safety of topical ruxolitinib cream for the treatment of vitiligo: A systematic review and meta-analysis of randomized controlled trials Document link: https://onlinelibrary.wiley.com/doi/10.1111/jocd.15921 Document source: Journal of Cosmetic Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients Document link: https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.0021 Document source: Jama Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Topical anti-inflammatory treatments for eczema: network meta-analysis Document link: https://www.cochranelibrary.com/resolve/doi?DOI=10.1002/14651858.CD015064.pub2 Document source: The Cochrane Database of Systematic Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis Document link: https://onlinelibrary.wiley.com/doi/10.1111/cea.14556 Document source: Clinical and Experimental Allergy : Journal of the British Society for Allergy Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis Document link: https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-024-02653-7 Document source: Systematic Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies Document link: https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(22)02688-3 Document source: Journal of the American Academy of Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review Document link: https://onlinelibrary.wiley.com/doi/10.1111/exd.14753 Document source: Experimental Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis Document link: https://link.springer.com/article/10.1007/s11096-023-01569-x Document source: International Journal of Clinical Pharmacy Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo Document link: https://jddonline.com/articles/dermatology/S1545961623P0664X Document source: Journal of Drugs in Dermatology : Jdd Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis Document link: https://linkinghub.elsevier.com/retrieve/pii/S2405-8440(23)09222-8 Document source: Heliyon Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis Document link: https://www.tandfonline.com/doi/full/10.1080/09546634.2020.1735615 Document source: The Journal of Dermatological Treatment Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis Document link: https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.16126 Document source: The Journal of Dermatology Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis Document link: https://onlinelibrary.wiley.com/doi/10.1111/dth.15098 Document source: Dermatologic Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Document title: A living WHO guideline on drugs for COVID-19. Document link: https://www.bmj.com/content/370/bmj.m3379.long Document source: WHO Document type: Clinical Practice Guidelines Document year: 2020

Nemluvio

Indications

Indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies
Indicated for the treatment of adults with prurigo nodularis

Document title: English version of clinical practice guidelines for the management of atopic dermatitis 2024 Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17544 Document source: The Journal of Dermatology Document type: Clinical Practice Guidelines Document year: 2025

Document title: Efficacy and Safety of Nemolizumab in Patients With Prurigo Nodularis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Document link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11894857/pdf/cureus-0017-00000078761.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2025

Document title: Nemluvio (nemolizumab-ilto) Prescribing Information. Document link: https://www.galderma.com/sites/default/files/2024-12/Nemluvio_Dual%20PI%20for%20website%2013Dec24.pdf Document source: Galderma Laboratories, L.P., Dallas, TX Document type: Product Monograph / Prescribing Information Document year: 2024

Document title: Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options Document link: https://karger.com/DRM/article/doi/10.1159/000523700 Document source: Dermatology (basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis Document link: https://onlinelibrary.wiley.com/doi/10.1111/all.14870 Document source: Allergy Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials Document link: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.825312/full Document source: Frontiers in Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2022

Document title: Biological Therapies for Atopic Dermatitis: A Systematic Review Document link: https://karger.com/DRM/article/doi/10.1159/000514535 Document source: Dermatology (basel, Switzerland) Document type: Systematic Reviews / Meta-Analyses Document year: 2021

Adquey

Indications

Indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis

Document title: Adquey (difamilast) Prescribing Information Document link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219474Orig1s000lbl.pdf Document source: Acrotech Biopharma Inc East Windsor, NJ Document type: Product Monograph / Prescribing Information Document year: 2026

Document title: Systematic Literature Review and Network Meta-Analysis of Clinical Efficacy and Safety of Topical Treatments for Patients with Atopic Dermatitis Document link: https://link.springer.com/article/10.1007/s13555-025-01390-6 Document source: Dermatology and Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2025

Document title: English version of clinical practice guidelines for themanagement of atopic dermatitis 2024 Document link: https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17544 Document source: Journal of Dermatology Document type: Clinical Practice Guidelines Document year: 2024

Document title: Topical anti-inflammatory treatments for eczema: network meta-analysis Document link: http://doi.wiley.com/10.1002/14651858.CD015064.pub2 Document source: The Cochrane Database of Systematic Reviews Document type: Systematic Reviews / Meta-Analyses Document year: 2024

Document title: Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials Document link: https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(23)01113-2 Document source: The Journal of Allergy and Clinical Immunology Document type: Systematic Reviews / Meta-Analyses Document year: 2023

Document title: Clinical efficacy and safety of topical difamilast in the treatment of patients with atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials Document link: https://www.tandfonline.com/doi/10.1080/17512433.2022.2134114?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Document source: Expert Review of Clinical Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2022